 |
Top 20 ALS startups
Oct 12, 2024 | By Jason Kwon | 15 |
These startups develop new ALS treatments and diagnostics technologies, like AI-powered imaging and drug-discovery, gene therapy, stem cells, communication apps and gadgets.
1
Country: USA | Funding: $634M
Annexon Biosciences a biotechnology company, discovers and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Annexon Biosciences a biotechnology company, discovers and developing novel therapeutics for neurodegenerative and autoimmune disorders.
2
Country: Israel | Funding: $63.1M
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
3
Country: USA | Funding: $1.1B
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
4
Country: USA | Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
5
Country: USA | Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
6
Country: USA | Funding: $181.2M
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
Skyhawk's is developing small molecule therapeutics that correct RNA expression.Their proprietary technology enables the rational design of small molecules that target the RNA splicing process.They are now developing drug candidates for cancer, neurological disease, and rare disease.
7
Country: Netherlands | Funding: €160M
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
VectorY Therapeutics develops gene therapies against amyotrophic lateral sclerosis (ALS) and Alzhiemer’s disease.
8
Country: Australia | Funding: $145M
Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.
Synchron manufactures and markets a medical device that can be delivered to the brain with a catheter to record neuron signals that might be used to control an advanced prosthetic.
9
Country: USA | Funding: $137.4M
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
10
Country: USA | Funding: $135.5M
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
QurAlis is specifically focused on discovering & developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.
